Literature DB >> 24700398

"Mild" vs. "long" protocol for controlled ovarian hyperstimulation in patients with expected poor ovarian responsiveness undergoing in vitro fertilization (IVF): a large prospective randomized trial.

Alberto Revelli1, Alessandra Chiadò, Paola Dalmasso, Veronica Stabile, Francesca Evangelista, Gemma Basso, Chiara Benedetto.   

Abstract

BACKGROUND: This large prospective, randomized study was designed to compare the "mild" protocol with clomiphene citrate, low-dose gonadotropins and a GnRH-antagonist (CC/Gn/GnRH-ant protocol) with the "long" protocol with a GnRH-agonist and high-dose Gn for the controlled ovarian hyperstimulation (COH) of patients with expected poor ovarian responsiveness undergoing IVF.
MATERIALS AND METHODS: A total of 695 women with clinical, endocrine and ultrasound characteristics suggesting a low ovarian reserve and a poor responsiveness to COH were recruited and randomly assigned to receive the CC/Gn/GnRH-ant "mild" protocol (mild group, n = 355) or the "long" protocol with high-dose Gn (long group, n = 340).
RESULTS: The "mild" stimulation led to significantly shorter follicular phase, lower consumption of exogenous Gn and lower peak estradiol level than the "long" regimen. With the "long" protocol, significantly less cycles were cancelled due to the lack of ovarian response; further, it obtained significantly more oocytes, more mature oocytes, more embryos, and a thicker endometrium. As for the final IVF outcome, however, the two stimulation regimens obtained comparable implantation rate, clinical pregnancy rate, and ongoing pregnancy rate at 12 weeks.
CONCLUSIONS: In conclusion, the "mild" CC/Gn/GnRH-ant stimulation protocol is a valid alternative to the long protocol with high Gn dose as it obtains a comparable success rate and requires significantly less medications, with an obvious economical advantage.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24700398      PMCID: PMC4096882          DOI: 10.1007/s10815-014-0227-y

Source DB:  PubMed          Journal:  J Assist Reprod Genet        ISSN: 1058-0468            Impact factor:   3.412


  26 in total

Review 1.  Regulation of ovarian follicular development in primates: facts and hypotheses.

Authors:  A Gougeon
Journal:  Endocr Rev       Date:  1996-04       Impact factor: 19.871

Review 2.  Clomiphene citrate: mechanism(s) and site(s) of action--a hypothesis revisited.

Authors:  E Y Adashi
Journal:  Fertil Steril       Date:  1984-09       Impact factor: 7.329

3.  Comparison of outcome of clomiphene citrate/human menopausal gonadotropin/cetrorelix protocol and buserelin long protocol--a randomized study.

Authors:  Yu-Hung Lin; Jiann-Loung Hwang; Kok-Min Seow; Lee-Wen Huang; Bih-Chwen Hsieh; Chi-Ruey Tzeng
Journal:  Gynecol Endocrinol       Date:  2006-06       Impact factor: 2.260

4.  GnRH antagonist improved blastocyst quality and pregnancy outcome after multiple failures of IVF/ICSI-ET with a GnRH agonist protocol.

Authors:  Katsuhiko Takahashi; Tetsunori Mukaida; Tatsuhiro Tomiyama; Tetsuya Goto; Chikahiro Oka
Journal:  J Assist Reprod Genet       Date:  2004-09       Impact factor: 3.412

5.  Will GnRH antagonists provide new hope for patients considered 'difficult responders' to GnRH agonist protocols?

Authors:  I Craft; A Gorgy; J Hill; D Menon; B Podsiadly
Journal:  Hum Reprod       Date:  1999-12       Impact factor: 6.918

Review 6.  Clomiphene combined with gonadotropins and GnRH antagonist versus conventional controlled ovarian hyperstimulation without clomiphene in women undergoing assisted reproductive techniques: systematic review and meta-analysis.

Authors:  J B P Figueiredo; C O Nastri; A D D Vieira; W P Martins
Journal:  Arch Gynecol Obstet       Date:  2012-12-19       Impact factor: 2.344

7.  A novel protocol of ovulation induction with delayed gonadotropin-releasing hormone antagonist administration combined with high-dose recombinant follicle-stimulating hormone and clomiphene citrate for poor responders and women over 35 years.

Authors:  Giuseppe D'Amato; Ettore Caroppo; Annamaria Pasquadibisceglie; Domenico Carone; Angela Vitti; Giovanni Michele Vizziello
Journal:  Fertil Steril       Date:  2004-06       Impact factor: 7.329

8.  Preliminary experience with a combination of clomiphene and variable dosages of menopausal gonadotropins for enhanced follicular recruitment.

Authors:  M M Quigley; C L Schmidt; P J Beauchamp; N F Maklad; A S Berkowitz; D P Wolf
Journal:  J In Vitro Fert Embryo Transf       Date:  1985-03

Review 9.  Clinical management of low ovarian response to stimulation for IVF: a systematic review.

Authors:  B C Tarlatzis; L Zepiridis; G Grimbizis; J Bontis
Journal:  Hum Reprod Update       Date:  2003 Jan-Feb       Impact factor: 15.610

10.  High-dose human menopausal gonadotropin stimulation in poor responders does not improve in vitro fertilization outcome.

Authors:  J A Land; M I Yarmolinskaya; J C Dumoulin; J L Evers
Journal:  Fertil Steril       Date:  1996-05       Impact factor: 7.329

View more
  23 in total

1.  Why more is less and less is more when it comes to ovarian stimulation.

Authors:  Zeev Blumenfeld
Journal:  J Assist Reprod Genet       Date:  2015-10-19       Impact factor: 3.412

2.  Preliminary proteomic analysis on the alterations in follicular fluid proteins from women undergoing natural cycles or controlled ovarian hyperstimulation.

Authors:  Yan-Ting Wu; Yan Wu; Jun-Yu Zhang; Ning-Ning Hou; Ai-Xia Liu; Jie-Xue Pan; Jie-Yang Lu; Jian-Zhong Sheng; He-Feng Huang
Journal:  J Assist Reprod Genet       Date:  2015-01-18       Impact factor: 3.412

3.  Mild Versus Conventional Ovarian Stimulation for Poor Responders Undergoing IVF/ICSI.

Authors:  Charalampos Siristatidis; George Salamalekis; Konstantinos Dafopoulos; George Basios; Paraskevi Vogiatzi; Nikolaos Papantoniou
Journal:  In Vivo       Date:  2017 Mar-Apr       Impact factor: 2.155

4.  Minimal ovarian stimulation is an alternative to conventional protocols for older women according to Poseidon's stratification: a retrospective multicenter cohort study.

Authors:  Mauro Cozzolino; Gustavo Nardini Cecchino; Ernesto Bosch; Juan Antonio Garcia-Velasco; Nicolás Garrido
Journal:  J Assist Reprod Genet       Date:  2021-04-13       Impact factor: 3.357

5.  Comparative prospective study of 2 ovarian stimulation protocols in poor responders: effect on implantation rate and ongoing pregnancy.

Authors:  Philippe Merviel; Rosalie Cabry-Goubet; Emmanuelle Lourdel; Aviva Devaux; Naima Belhadri-Mansouri; Henri Copin; Moncef Benkhalifa
Journal:  Reprod Health       Date:  2015-05-30       Impact factor: 3.223

6.  Comparison of GnRH agonist, GnRH antagonist, and GnRH antagonist mild protocol of controlled ovarian hyperstimulation in good prognosis patients.

Authors:  Martin Stimpfel; Eda Vrtacnik-Bokal; Barbara Pozlep; Irma Virant-Klun
Journal:  Int J Endocrinol       Date:  2015-03-17       Impact factor: 3.257

7.  Association between GnRH Receptor Polymorphisms and Luteinizing Hormone Levels for Low Ovarian Reserve Infertile Women.

Authors:  Shun-Long Weng; Shu-Ling Tzeng; Chun-I Lee; Chung-Hsien Liu; Chun-Chia Huang; Shun-Fa Yang; Maw-Sheng Lee; Tsung-Hsien Lee
Journal:  Int J Environ Res Public Health       Date:  2021-06-30       Impact factor: 3.390

8.  The association of serum estradiol level with outcomes of clomiphene citrate/human menopausal gonadotropin ovarian stimulation for in vitro fertilization and embryo transfer.

Authors:  Xiao-Jin Zhang; Su-Ying Liu; Wei Fu; Xiao-Xi Sun
Journal:  Reprod Biol Endocrinol       Date:  2015-10-06       Impact factor: 5.211

9.  Comparison Pregnancy Outcomes Between Minimal Stimulation Protocol and Conventional GnRH Antagonist Protocols in Poor Ovarian Responders.

Authors:  Shamim Pilehvari; Ensieh ShahrokhTehraninejad; Batool Hosseinrashidi; Fatemeh Keikhah; Fedyeh Haghollahi; Elham Aziminekoo
Journal:  J Family Reprod Health       Date:  2016-03

10.  The IMSI Procedure Improves Laboratory and Clinical Outcomes Without Compromising the Aneuploidy Rate When Compared to the Classical ICSI Procedure.

Authors:  Daniel Luna; Roly Hilario; Julio Dueñas-Chacón; Rocío Romero; Patricia Zavala; Lucy Villegas; Javier García-Ferreyra
Journal:  Clin Med Insights Reprod Health       Date:  2015-11-12
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.